Kojin Therapeutics

Kojin Therapeutics is the first biopharmaceutical company to use a proprietary approach to study cell states and ferroptosis biology, developing novel targeted therapies for diseases with high unmet needs. Founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, Kojin is accelerating a drug discovery platform that links complex cell states with known biochemical processes, such as ferroptosis or iron-dependent cell death, enabling the development of a broad range of selective therapies for difficult-to-treat diseases.